Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13844364 | 0.88 | HTT (0.53) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL14105738 | 0.88 | MAPT (0.56) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL3718605 | 0.87 | MAPT (0.52) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL13844444 | 0.86 | RAB9A (0.63) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL12325422 | 0.86 | MAPT (0.55) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL12325784 | 0.85 | HTT (0.50) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL12325437 | 0.84 | SMN1; SMN2 (0.50) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL14105332 | 0.84 | MAPT (0.49) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL14105822 | 0.84 | PPARG (0.55) | HTTSMN1; SMN2MAPTNLRP3KDM4E | |
| SCHEMBL13844340 | 0.84 | RAB9A (0.54) | HTTSMN1; SMN2MAPTNLRP3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436031-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009005551-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | HTT 3865/4885SMN1; SMN2 4868/4885MAPT 4415/4885 |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | HTT 3865/4885SMN1; SMN2 4868/4885MAPT 4415/4885 |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | CREBBP, JUN, IRF3 | HTT 4281/4885SMN1; SMN2 4876/4885MAPT 4703/4885 |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JUN, CREBBP, TFEB | HTT 3865/4885SMN1; SMN2 4868/4885MAPT 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.